AI Article Synopsis

  • RGC-32 is a key regulator in the TGF-β signaling pathway and influences the maturation and reactivity of spinal cord astrocytes.
  • Mice lacking RGC-32 exhibit an immature astrocyte phenotype, characterized by increased proliferation and the expression of progenitor markers, making them less capable of responding to acute inflammation.
  • Next-generation sequencing reveals that RGC-32 is necessary for the up-regulation of genes involved in brain development and tissue remodeling, and its absence leads to significant changes in astrocytic gene expression and an increased presence of radial glia cells.

Article Abstract

Response Gene to Complement 32 (RGC-32) is an important mediator of the TGF-β signaling pathway, and an increasing amount of evidence implicates this protein in regulating astrocyte biology. We showed recently that spinal cord astrocytes in mice lacking RGC-32 display an immature phenotype reminiscent of progenitors and radial glia, with an overall elongated morphology, increased proliferative capacity, and increased expression of progenitor markers when compared to their wild-type (WT) counterparts that make them incapable of undergoing reactive changes during the acute phase of experimental autoimmune encephalomyelitis (EAE). Here, in order to decipher the molecular networks underlying RGC-32's ability to regulate astrocytic maturation and reactivity, we performed next-generation sequencing of RNA from WT and RGC-32 knockout (KO) neonatal mouse brain astrocytes, either unstimulated or stimulated with the pleiotropic cytokine TGF-β. Pathway enrichment analysis showed that RGC-32 is critical for the TGF-β-induced up-regulation of transcripts encoding proteins involved in brain development and tissue remodeling, such as axonal guidance molecules, transcription factors, extracellular matrix (ECM)-related proteins, and proteoglycans. Our next-generation sequencing of RNA analysis also demonstrated that a lack of RGC-32 results in a significant induction of WD repeat and FYVE domain-containing protein 1 (Wdfy1) and stanniocalcin-1 (Stc1). Immunohistochemical analysis of spinal cords isolated from normal adult mice and mice with EAE at the peak of disease showed that RGC-32 is necessary for the expression of ephrin receptor type A7 in reactive astrocytes, and that the lack of RGC-32 results in a higher number of homeodomain-only protein homeobox (HOPX) and CD133 radial glia cells. Collectively, these findings suggest that RGC-32 plays a major role in modulating the transcriptomic changes in astrocytes that ultimately lead to molecular programs involved in astrocytic differentiation and reactive changes during neuroinflammation.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358671PMC
http://dx.doi.org/10.3389/fimmu.2021.705308DOI Listing

Publication Analysis

Top Keywords

rgc-32
9
transcriptomic changes
8
radial glia
8
reactive changes
8
next-generation sequencing
8
sequencing rna
8
lack rgc-32
8
rgc-32 acts
4
acts hub
4
hub regulate
4

Similar Publications

It has been well established that tumor-infiltrating lymphocytes (TILs) play a critical role in the pathogenesis and progression of clear cell renal cell carcinoma (ccRCC). However, the mechanism on the interactions between TILs and tumor cells in the tumor-immune microenvironment remains unclear. In the present study, the expression of Response Gene to Complement 32 (RGC-32) was evaluated using immunohistochemistry.

View Article and Find Full Text PDF

Metformin Inhibits the Progression of Pancreatic Cancer Through Regulating miR-378a-3p/VEGFA/RGC-32 Axis.

Cancer Med

December 2024

Department of Gastroenterology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.

Background: Pancreatic cancer (PC) is a major contributor to global cancer-related mortality. While the inhibitory effect of metformin (Met) on PC has been reported, the underlying mechanism remains elusive.

Methods: We established BxPC-3 cell models with miR-378a-3p and VEGFA knockdown.

View Article and Find Full Text PDF

Regular assessment of disease activity in relapsing-remitting multiple sclerosis (RRMS) is required to optimize clinical outcomes. Biomarkers can be a valuable tool for measuring disease activity in multiple sclerosis (MS) if they reflect the pathological processes underlying MS pathogenicity. In this pilot study, we combined multiple biomarkers previously analyzed in RRMS patients into an MS disease activity (MSDA) score to evaluate their ability to predict relapses and treatment response to glatiramer acetate (GA).

View Article and Find Full Text PDF

RGC-32 mediates proinflammatory and profibrotic pathways in immune-mediated kidney disease.

Clin Immunol

August 2024

Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address:

Article Synopsis
  • Systemic lupus erythematosus is an autoimmune disease causing damage to kidneys and organs, which was studied in the context of nephrotoxic nephritis (NTN) as a model for lupus nephritis.
  • The research focused on response gene to complement-32 (RGC-32), finding that its absence in RGC-32 knockout (KO) NTN mice led to reduced proteinuria, improved kidney function, and less severe kidney damage.
  • RGC-32 KO mice also showed decreased recruitment of certain immune cells and less renal fibrosis, suggesting that RGC-32 could be a promising target for new treatments aimed at combatting conditions like lupus nephritis.
View Article and Find Full Text PDF

RGC-32 facilitates pancreatic cancer via activating Wnt/β-catenin signaling.

Cell Mol Biol (Noisy-le-grand)

December 2023

Department of Gastroenterology, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330006, China.

Longitudinal studies have indicated the facilitating effect of RGC-32 during diverse disease progression including pancreatic cancer, yet the systematic and detailed effect of RGC-32 during pancreatic cancer is largely unknowable. For this purpose, we took advantage of the pancreatic cancer cell line (BXPC3) with RGC-32 expression and then modulated its expression by lentivirus-mediated knockdown (shRGC-32) and overexpression (pcDNA-RGC-32). To verify the effect of Wnt/β-catenin signaling in RGC-32-based tumorigenicity, we added the agonist CT99021 to the shRGC-32 BXPC3 cell line and pancreatic cancer mouse model.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!